Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
11 Dec 2020
Historique:
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 8 1 2021
Statut: ppublish

Résumé

Hypofractionation for localized prostate cancer treatment is rapidly spreading in the medical community and it is supported by radiobiological evidences (lower α/β ratio compared with surrounding tissues). Stereotactic body radiation therapy (SBRT) is a technique to administer high doses with great precision, which is commonly performed with CyberKnife (CK) in prostate cancer treatment. Since the CyberKnife (CK) is not available at all radiotherapy center, alternative SBRT techniques are available such as Volumetric Modulated Arc Therapy (VMAT) and Helical Tomotherapy (HT). The aim of the present study was to compare the dosimetric differences between the CK, VMAT, and HT plans for localized prostate cancer treatment.Seventeenpatients have been recruited and replanned using VMAT and HT to this purpose: they received the treatment using the CK with a prescription of 36.25 Gy in 5 fractions; bladder, rectum and penis bulb were considered as organs at risk (OAR). In order to compare the techniques, we considered DVHs, PTV coverage, Conformity Index and new Conformity Index, Homogeneity Index, beam-on time and OARs received dose.The 3 treatments methods showed a comparable coverage of the lesion (PTV 95%: 99.8 ± 0.4% CK; 98.5 ± 0.8% VMAT; 99.4 ± 0.5% HT. P < .05) and good sparing of OARs. Nevertheless, the beam-on time showed a significant difference (37 ± 9 m CK; 7.1 ± 0.3 m VMAT; 17 ± 2 m HT. P < .05).Our results showed that, although CK is the best SBRT technique for prostate cancer treatment, in case this technology is not available, it can be replaced by a similar treatment delivered by VMAT technique. VMAT can be administrated only if it has an appropriate Image Guided Radiation Therapy (IGRT) tracking system.

Identifiants

pubmed: 33327317
doi: 10.1097/MD.0000000000023574
pii: 00005792-202012110-00098
pmc: PMC7738085
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e23574

Références

Acta Oncol. 2005;44(3):265-76
pubmed: 16076699
Lancet Oncol. 2016 Apr;17(4):464-474
pubmed: 26968359
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Technol Cancer Res Treat. 2009 Oct;8(5):387-92
pubmed: 19754215
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1271-8
pubmed: 20934277
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):58-63
pubmed: 20133073
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):11-8
pubmed: 20047800
Rev Urol. 2008 Spring;10(2):111-9
pubmed: 18660852
Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):411-6
pubmed: 26696780
Rep Pract Oncol Radiother. 2014 Nov 18;20(2):99-103
pubmed: 25859398
Eur Urol. 2019 Dec;76(6):790-813
pubmed: 31587989
Curr Oncol. 2015 Feb;22(1):10-2
pubmed: 25684983
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
pubmed: 11429230
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
pubmed: 10192361
Radiat Oncol. 2013 Jul 08;8:171
pubmed: 23835141
Clin Oncol (R Coll Radiol). 2014 Jan;26(1):4-9
pubmed: 24071450
Acta Oncol. 2012 Nov;51(8):963-74
pubmed: 22966812
J Xray Sci Technol. 2017;25(3):465-477
pubmed: 28157113
J Appl Clin Med Phys. 2011 Feb 08;12(2):3368
pubmed: 21587185
Cancer Treat Rev. 2016 Nov;50:48-60
pubmed: 27631875
Clin Oncol (R Coll Radiol). 2015 May;27(5):260-9
pubmed: 25797579
Technol Cancer Res Treat. 2010 Dec;9(6):575-82
pubmed: 21070079
Semin Radiat Oncol. 2008 Oct;18(4):215-22
pubmed: 18725106
Technol Cancer Res Treat. 2017 Apr;16(2):238-245
pubmed: 28279147
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):877-82
pubmed: 21300474
Lancet Oncol. 2015 Dec;16(16):1605-16
pubmed: 26522334
Radiat Oncol. 2011 Jan 10;6:3
pubmed: 21219625
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
pubmed: 21324610
CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
pubmed: 22700443
J Clin Oncol. 2013 Nov 1;31(31):3860-8
pubmed: 24101042
J Clin Oncol. 2005 Sep 1;23(25):6132-8
pubmed: 16135479
Expert Rev Anticancer Ther. 2014 May;14(5):553-64
pubmed: 24579695
Phys Med. 2014 Sep;30(6):654-61
pubmed: 24726212

Auteurs

Marcello Serra (M)

Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II - Napoli.

Gianluca Ametrano (G)

Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples.

Valentina Borzillo (V)

Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples.

Maria Quarto (M)

Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II - Napoli.

Matteo Muto (M)

Dipartimento Onco-Ematologico Radioterapia, Azienda ospedaliera San Giuseppe Moscati - Avellino, Italy.

Rossella Di Franco (R)

Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples.

Savino Federica (S)

Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II - Napoli.

Filomena Loffredo (F)

Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II - Napoli.

Muto Paolo (M)

Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH